TRACON to Report First Quarter 2020 Financial Results and Company Highlights on May 13, 2020
Rhea-AI Summary
TRACON Pharmaceuticals (NASDAQ:TCON) announced it will report its first quarter 2020 financial and operational results on May 13, 2020, post market close. The company will also host a conference call at 4:30 pm ET for discussions on corporate activities and results. TRACON is focused on developing targeted therapies for cancer and has a pipeline that includes multiple drug candidates, including Envafolimab for sarcoma and TRC102 for lung cancer. The company seeks partnerships to manage regulatory and clinical development and shares costs and risks.
Positive
- Plans to start a registrational trial for Envafolimab for sarcoma in H2 2020.
- Active pipeline includes multiple promising drug candidates for various cancers.
Negative
- None.
News Market Reaction – TCON
On the day this news was published, TCON declined 3.11%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its first quarter 2020 financial and operating results after the close of U.S. financial markets on Wednesday, May 13, 2020. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | May 13, 2020 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 6453397 |
| Via web: | www.traconpharma.com; “Events and Presentations” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a subcutaneous PD-L1 single-domain antibody being developed for the treatment of sarcoma with the goal of starting a registrational trial in the U.S. in the second half of 2020; TRC102, a small molecule drug candidate being developed for the treatment of lung cancer; TRC253, a small molecule drug candidate being developed for the treatment of prostate cancer; and TJ004309, a CD73 antibody being developed for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Andrew McDonald |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | 646-597-6987 |
| mwiggins@traconpharma.com | Andrew@lifesciadvisors.com |
FAQ
When will TRACON Pharmaceuticals report its Q1 2020 financial results?
What time is the TRACON Pharmaceuticals conference call?
What are the key drug candidates in TRACON's pipeline?
How does TRACON Pharmaceuticals plan to develop its products?
